A new cytokine: the possible effect pathway of methionine enkephalin

Table 1 Antagonism of different of concentrations of monoclonal antibody (MAb) to methionine enkephalin (MENK) at 1 × 10^-6 mol·L^-1 on the activity of PKA in cytosol and membrane of NS-1 cells. n = 3 from 3 independent experiments. ^bP < 0.05 and ^cP < 0.01 vs control, ^eP < 0.05 and ^fP < 0.01 vs group 2

MENK+MAb	Activity of PKA in cytosol/pmol·mg-1·min-1	Activity of PKA in membrane/pmol·mg-1·min-1
Control	21.10 ± 1.09	6.81 ± 1.63
MENK	24.69 ± 0.49c	10.42 ± 0.71b
MENK+10-11 mol·L-1 MAb	29.98 ± 0.59cf	13.73 ± 1.84ce
MENK+10-10 mol·L-1 MAb	20.03 ± 1.47	7.59 ± 0.35e
MENK+10-9 mol·L-1 MAb	12.99 ± 0.95cf	7.11 ± 2.04e

Table 2 Antagonism of different of concentrations of monoclonal antibody (MAb) to methionine enkephalin (MENK) at 1 × 10^-6 mol·L^-1 on the intracellular activity of PKC in NS-1 cells. n = 3 from 3 independent experiments. ^bP < 0.05 vs control, ^eP < 0.05 and ^fP < 0.05 vs group 2

MENK+MAb	Activity of PKC (pmol·mg-1·min-1)
Control	3.06 ± 0.19
MENK	2.26 ± 0.03b
MENK+10-11 mol·L-1 MAb	2.92 ± 0.02e
MENK+10-10 mol·L-1 MAb	2.80 ± 0.4e
MENK+10-9 mol·L-1 MAb	3.13 ± 0.45ff